Regenicin, Inc. (OTCPK: RGIN)
Health Care · Biotechnology · US
$—
— today · — 1Y
Regenicin, Inc. (OTCPK: RGIN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $15.35K and employs 3 people.
trading between 0.00 and 0.75.
Tweenvest scores Regenicin, Inc. across four factors: quality 14/100. Its strongest factor is quality.
RGIN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $15.35K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 39.09
- 52-week high
- $0.75
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 153.48M
- Employees
- 3
- Next earnings
- —
About Regenicin, Inc.
Regenicin, Inc. is dedicated to the development and commercialization of advanced tissue-engineered skin replacement technologies. Its product line features NovaDerm, a sophisticated multi-layered living and cultured skin substitute engineered for treating burn injuries, alongside TempaDerm, which addresses more localized wound areas like ulcers. These innovative solutions aim to rejuvenate the characteristics of healthy human skin, finding application in burn therapy, chronic wound management, and various plastic surgery procedures. Incorporated in 2007 and based in Little Falls, New Jersey, the company was previously known as Windstar, Inc., adopting the Regenicin, Inc. name in July 2010.
- ISIN
- US75887Q1022
- Founded
- 2007
- Listed since
- Nov 16, 2009
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.